Over 80 cell and gene therapy (CGT) products were in active clinical trials in China as of early 2026, making the country the second-largest CGT clinical trial market globally after the United States. With China’s NMPA having approved seven CGT products to date — including the world’s first CAR-T therapy for relapsed/refractory multiple myeloma — the regulatory environment for cell and gene therapy trials has matured rapidly. However, conducting CGT trials in China involves navigating a uniquely complex regulatory framework that combines elements of drug development, biological product regulation, and cellular therapy-specific oversight. This guide provides a complete walkthrough for foreign biotech companies planning to conduct CGT clinical trials in China under the 2026 regulatory framework, covering IND filing, trial design considerations, CMC requirements, and post-market obligations.
Understanding China’s CGT Regulatory Framework
The regulatory landscape for cell and gene therapy in China is defined by multiple complementary regulations administered primarily by the NMPA’s Center for Drug Evaluation (CDE, 国家药品监督管理局药品审评中心, guójiā yàopǐn jiāndū guǎnlǐ jú yàopǐn shěnpíng zhōngxīn). The foundational document is the “Guidelines for Clinical Research and Evaluation of Cell Therapy Products” (细胞治疗产品临床研究和评价指导原则, xìbāo zhìliáo chǎnpǐn línchuáng yánjiū hé píngjià zhǐdǎo yuánzé), first issued in 2021 and updated in 2025. Product-specific guidance documents cover CAR-T cells, TCR-T cells, tumor-infiltrating lymphocytes (TIL), natural killer (NK) cells, mesenchymal stem cells (MSC), and gene editing therapies using CRISPR/Cas9 and other platforms.
The regulatory framework distinguishes between two primary pathways: (1) Investigational New Drug (IND) filing for commercial development, which follows the CDE’s 2009 Standards for Drug Registration (药品注册管理办法, yàopǐn zhùcè guǎnlǐ bànfǎ) as amended through 2025, and (2) Clinical Research Filing for early-stage, investigator-initiated trials conducted at NMPA-accredited hospitals under the National Health Commission’s (NHC) 2015 Administrative Measures on Stem Cell Clinical Research. The 2025 consolidated regulations streamlined these pathways, clarified GMP requirements for CGT products, and introduced a “priority review” designation for therapies targeting diseases with no effective treatment options in China (defined as conditions affecting ≥ 200,000 patients with ≤ 2 approved therapies).
Prerequisites and Documentation Requirements
Before filing an IND for a CGT product, sponsors must assemble a complete dossier meeting CDE’s Format 80 (CTD-compliant) specifications. Compared to conventional small-molecule drugs, CGT INDs require substantially more extensive characterization data due to the biological complexity and variability inherent in living cell products.
| Document Module | Key Content Requirements | CGT-Specific Considerations |
|---|---|---|
| Module 1: Administrative Information | Sponsor qualification, manufacturing license, letter of authorization, patent status | GMP certificate for cell product manufacturing (2024 GMP Annex for CGT products required) |
| Module 2: Quality Overall Summary | Product characterization, potency assay, release specifications | Identity, purity, potency, viability, sterility specifications; vector characterization for gene therapy products |
| Module 3: CMC (Chemistry, Manufacturing, Controls) | Manufacturing process, in-process controls, stability, container closure | Donor screening criteria, starting materials (leukapheresis, vector bank), cryopreservation validation, transport validation |
| Module 4: Non-Clinical Study Reports | Pharmacology, pharmacokinetics (biodistribution), toxicology | Tumorigenicity assessment (in vivo and in vitro), off-target effects for gene editing, vector integration analysis |
| Module 5: Clinical Study Reports | Trial protocol, investigator brochure, IB, informed consent form | Long-term follow-up protocol (minimum 15 years for gene therapy per 2025 NMPA guidance), bridging study plan for foreign data |
| GCP Certification | All trial sites must have NMPA GCP certification | CGT-specific GCP training for investigators required; 2026 update mandates annual refresher |
| Ethics Committee Approval | From each participating hospital’s IRB/EC | Ethical review for genetic modification must include bioethics committee member per 2025 Bioethics Review Guidelines |
Per the 2025 CDE Technical Guidance for CGT IND Submissions, incomplete Module 3 dossiers (CMC) accounted for 62% of all CGT IND deficiencies in 2024–2025, with vector characterization and potency assay development being the most frequently cited deficiencies (Source: CDE Annual Drug Evaluation Report 2025).
Step-by-Step CGT Clinical Trial Process
Conducting a cell or gene therapy clinical trial in China follows an eight-step sequence from preclinical preparation to trial completion. The timeline from IND filing to first patient dosing is typically 12–18 months for CGT products, compared to 6–9 months for conventional biologics, due to the additional manufacturing and characterization requirements.
- Pre-IND Meeting Request — Submit a pre-IND meeting request to CDE at least 60 days before the formal IND submission. The pre-IND meeting is compulsory for CGT products under the 2024 regulations. Prepare a pre-IND briefing package covering: product summary, proposed indication, clinical trial design, CMC strategy, and key questions for CDE. CDE provides written responses within 30 working days; meeting scheduling takes an additional 15–20 working days post-response issuance.
- Manufacturing Process Validation — Before IND filing, complete full manufacturing process validation under GMP conditions per the 2024 CGT GMP Annex (细胞治疗产品生产质量管理规范, xìbāo zhìliáo chǎnpǐn shēngchǎn zhìliàng guǎnlǐ guīfàn). This includes: vector production (for gene-modified cell therapies), cell processing and expansion, quality control release testing, and cryopreservation validation. Three consecutive GMP batches at commercial scale are required for IND submission. Allow 6–9 months for manufacturing validation, including facility qualification.
- Non-Clinical Study Completion — Complete all required non-clinical studies per CDE’s “Non-Clinical Research Technical Guidelines for Cell Therapy Products” (2024 edition). Key requirements: (a) proof-of-concept in at least one relevant animal model demonstrating pharmacological activity, (b) biodistribution study confirming appropriate homing and persistence, (c) toxicology study in immunocompetent animals (or surrogate model) at the intended clinical dose, and (d) tumorigenicity assessment for pluripotent or extensively expanded cell products (minimum 26-week observation in immunocompromised mice). Studies conducted at NMPA-certified GLP laboratories require 6–12 months.
- Formal IND Submission to CDE — File the complete IND dossier via CDE’s electronic submission system (申请人之窗, shēnqǐngrén zhī chuāng). Standard acceptance review takes 5 working days; if incomplete, CDE issues a deficiency notice within 10 working days. After acceptance, CDE has 60 working days (approximately 12 weeks) for technical review. CGT products eligible for priority review (impacting survival or irreversible morbidity) receive a 40-working-day review timeline. Under the 2025 amended Drug Registration Regulations, orphan cell therapies targeting “rare diseases affecting ≤ 100,000 patients in China” may qualify for a 30-working-day expedited review.
- Supplemental Submission and Query Response — During CDE review, expect 1–3 rounds of written queries (补充资料, bǔchōng zīliào). Each query has a 40-working-day response deadline. Common CGT queries include: potency assay validation details, vector copy number stability data, long-term persistence monitoring plan, and comparability protocol for manufacturing changes. Incomplete or late responses result in automatic IND rejection. Budget 4–8 weeks per response cycle.
- IND Approval and Ethics Committee Submission — Upon IND approval (签发药物临床试验批准通知书, qiānfā yàowù línchuáng shìyàn pīzhǔn tōngzhī shū), submit to each participating hospital’s Ethics Committee (EC) for independent review. EC review in major CGT trial centers (Beijing, Shanghai, Guangzhou, Nanjing, Hangzhou) typically takes 30–45 working days. The 2025 Multi-Center Trial Guidelines require EC harmonization across sites, with the lead EC’s decision binding for all participating centers — reducing the traditional 2–4 month staggered EC approval to 45–60 days total.
- Trial Initiation and Patient Recruitment — After EC approval, register the trial on the China Clinical Trial Registration Center (ChiCTR) platform (Chinese Clinical Trial Register). Recruitment for CGT trials in China faces unique challenges: approximately 65% of CGT trials during 2023–2025 experienced recruitment delays due to patient eligibility criteria (specific biomarker profiles, prior therapy restrictions). China’s large patient population partially offsets this: for most oncology CGT indications (ALL, lymphoma, multiple myeloma, solid tumors), the addressable patient pool is 3–5× larger than in the US or EU due to higher incidence rates for certain tumors (especially liver, gastric, and esophageal cancers).
- Trial Conduct and Regulatory Reporting — CGT trial monitoring in China requires: (a) submission of safety reports to CDE within 7 days for serious adverse events (SAEs), (b) timely reporting of suspected unexpected serious adverse reactions (SUSARs) within 15 days, (c) 6-monthly DSMB progress reports, (d) annual IND safety update reports, and (e) long-term follow-up data at predefined intervals. For gene therapy products, the 2025 NMPA Gene Therapy Follow-Up Guidance mandates follow-up for a minimum of 15 years post-treatment with annual monitoring visits.
Timeline and Milestones
The full timeline from pre-IND preparation to trial initiation for a CGT product in China typically spans 18–30 months. The 2025 regulatory reforms — including the priority review pathway and the EC harmonization measures — have reduced timelines by 3–5 months compared to 2023 baseline figures.
| Milestone | Duration | Cumulative Time | Key Dependency |
|---|---|---|---|
| GMP Manufacturing Validation | 6–9 months | 6–9 months | Facility readiness; vector supply |
| Non-Clinical Studies | 6–12 months | 12–21 months | GLP lab scheduling; animal model availability |
| Pre-IND Meeting + Response | 3–4 months | 15–25 months | CDE scheduling; quality of briefing package |
| IND Filing + CDE Review | 3–5 months (standard) | 18–30 months | Deficiency response time |
| IND Filing + Priority Review | 2–3 months | 17–28 months | Priority designation eligibility |
| EC Approval (Harmonized) | 2–3 months | 20–33 months | Lead EC capacity |
| First Patient Dosed | 2–4 months post-EC | 22–37 months | Patient recruitment; site activation |
According to CDE’s 2025 Annual Statistics Report, the median time from IND filing to first patient dosed for CGT products was 18.3 months for priority-review products and 24.7 months for standard-review products, reflecting the significant impact of the regulatory pathway chosen.
Costs and Budget Considerations
Conducting a CGT clinical trial in China involves costs substantially different from both conventional drug trials in China and CGT trials in Western markets. Manufacturing costs for autologous cell products dominate the budget, particularly for CAR-T and TCR-T trials.
| Cost Category | Estimated Cost (RMB) | USD Equivalent | Notes |
|---|---|---|---|
| IND Preparation & Filing | 1,500,000–3,000,000 | 207,000–414,000 | CTD compilation, translation, regulatory consulting |
| GMP Facility Qualification | 5,000,000–15,000,000 | 690,000–2,070,000 | Biosafety Level 2+ (BSL-2+) facility; HVAC, cleanroom, QC lab |
| Manufacturing Validation (3 batches) | 3,000,000–8,000,000 | 414,000–1,104,000 | Materials, vector production, QC release testing |
| Non-Clinical Studies (GLP) | 2,000,000–5,000,000 | 276,000–690,000 | Animal models, toxicology, biodistribution, tumorigenicity |
| Clinical Trial Costs (Phase I, 20–30 patients) | 8,000,000–20,000,000 | 1,104,000–2,760,000 | Site fees, patient costs, cell manufacturing (CAR-T: ~300,000/patient) |
| CDE Review Fees | 200,000–500,000 | 27,600–69,000 | Priority review surcharge applies |
| Long-Term Follow-Up (15-year program) | 2,000,000–5,000,000 | 276,000–690,000 | Annual monitoring, data management, regulatory reporting |
| Regulatory Agent/Consulting (2-year engagement) | 2,000,000–4,000,000 | 276,000–552,000 | Local liaison, submission management, query response support |
Total budget for a Phase I CGT trial in China through IND approval and first patient dosed: approximately RMB 20–55 million (USD 2.8–7.6 million). This is 40–60% lower than comparable CGT trial costs in the US, where a Phase I CAR-T trial can exceed USD 15 million (USD 108 million RMB equivalent), making China an increasingly attractive destination for early-stage CGT development. (Source: Deloitte China Life Sciences Report 2025)
Common Pitfalls and How to Avoid Them
- Incomplete Vector Characterization for Gene-Modified Therapies — The CDE requires comprehensive characterization of viral vectors (lentivirus, AAV, retrovirus) including vector copy number, integration site analysis, and replication-competent lentivirus (RCL) testing. In 2024–2025, 37% of CGT IND rejections cited inadequate vector characterization. Use CDE’s 2025 Vector Characterization Technical Guidance as the definitive checklist; budget RMB 500,000–1,000,000 for vector-related studies.
- Underestimating the CMC Data Package — Chinese CGT regulations require more extensive CMC data than the US FDA or EU EMA for comparable products. Specifically: three commercial-scale batches (vs two for FDA/EMA), stability data at −80°C (vs −150°C for some FDA-accepted protocols), and transport validation under Chinese domestic shipping conditions. Plan for 9–12 months of CMC work, not the 6–8 months typical for Western submissions.
- Neglecting the MPS (Medical Products Safety) Evaluation — Under the 2025 Drug Registration Regulations, all CGT products require a formal Medical Product Safety (MPS) evaluation assessing product-class-specific risks including tumorigenicity, immunogenicity, and reactivation of latent viruses. This mandatory assessment requires dedicated studies and adds RMB 600,000–1,200,000 to development costs.
- Assuming Foreign Clinical Data Is Fully Accepted — While China now accepts foreign clinical data under the 2020–2025 ICH E17 and E19 harmonization initiatives, CDE requires a bridging study for CGT products unless the foreign data covers a Chinese-representative population. Race-specific immunogenicity data (HLA distribution, cytokine profiles) is particularly scrutinized. Plan for a bridging cohort of 8–15 Chinese patients even if relying on foreign efficacy data.
- Ignoring Dual-Use Technology Export Controls — Gene therapy technologies involving human genetic resources or gene editing tools may fall under China’s Export Control Law (出口管制法, chūkǒu guǎnzhì fǎ) and the Human Genetic Resources Administration (HGRAC) regulations. Foreign sponsors must submit a HGRAC filing for any transfer of genetic material into China for manufacturing or for any export of Chinese patient samples abroad for analysis. Failure to file carries fines of RMB 500,000–5,000,000 and potential criminal liability under the 2024 amended Biosecurity Law.
Post-Trial Obligations and Commercialization Pathway
After successful clinical trials, CGT product registration follows the New Drug Application (NDA) pathway under the Drug Registration Regulations. The CDE’s priority review pathway for breakthrough CGT therapies targets a 130-working-day review timeline (approximately 6 months) compared to the standard 200-working-day framework. For approved products, post-market requirements include: (1) risk management plan (RMP, 风险管理计划, fēngxiǎn guǎnlǐ jìhuà) submitted within 6 months of approval, (2) Phase IV clinical study commitments (typically 200–500 patients for CGT products), (3) annual safety update reports for 5 years post-approval, and (4) long-term follow-up continuation per the IND commitments. Market access considerations include negotiation with the National Healthcare Security Administration (NHSA) for NRDL (National Reimbursement Drug List) inclusion — as of 2026, no CGT product has secured nationwide reimbursement, though three CAR-T products have been included in city-level “City Commercial Insurance” programs covering 15–30% of treatment costs.
Where to Go From Here
Based on what you just read:
- Ready to act? Read [guide: CGT-IND-filing-checklist]
- Still comparing? See [comparison: CGT-regulatory-pathways-CN-vs-US-vs-EU]
- Need numbers? Try [tool: CGT-clinical-trial-cost-calculator]
— China Gateway 360 —
Remote China market entry support, built around execution.
